A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction HFpEF
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
October 21, 2025
End Date
October 31, 2026
Awarded By
Bristol-Myers Squibb Company
Start Date
October 21, 2025
End Date
October 31, 2026